Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on New Jersey Health Reporter.
June 2025
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
| 1 | ||||||
| 2 | 3 | 4 | 5 | 6 | 7 | 8 |
| 9 | 10 | 11 | 12 | 13 | 14 | 15 |
| 16 | 17 | 18 | 19 | 20 | 21 | 22 |
| 23 | 24 | 25 | 26 | 27 | 28 | 29 |
| 30 |
July 2025
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | |
| 7 | 8 | 9 | 10 | 11 | 12 | 13 |
| 14 | 15 | 16 | 17 | 18 | 19 | 20 |
| 21 | 22 | 23 | 24 | 25 | 26 | 27 |
| 28 | 29 | 30 | 31 |
August 2025
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | ||||
| 4 | 5 | 6 | 7 | 8 | 9 | 10 |
| 11 | 12 | 13 | 14 | 15 | 16 | 17 |
| 18 | 19 | 20 | 21 | 22 | 23 | 24 |
| 25 | 26 | 27 | 28 | 29 | 30 | 31 |
Press releases published on July 30, 2025
FDA Provides Trethera Clearance to Initiate TRE-515 Clinical Trial in Healthy Volunteers to Study Food Effect and Biomarkers
GlobeNewswire
·
July 30, 2025
LOS ANGELES, July 30, 2025 (GLOBE NEWSWIRE) -- Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company developing first-in-class therapies for cancer and autoimmune diseases, announced today that the U.S. Food and Drug Administration …
New Progyny Study Reveals Gap Between Perceptions and Realities in Women’s Health Benefits Coverage
GlobeNewswire
·
July 30, 2025
NEW YORK, July 30, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women’s health and family building solutions, today announced the results of their new national Women in the Workplace research conducted in partnership with …
BrainsWay Champions TMS Education with Sponsorship of Two Free CME Courses for Mental Health Professionals
GlobeNewswire
·
July 30, 2025
BURLINGTON, Mass. and JERUSALEM, Israel, July 30, 2025 (GLOBE NEWSWIRE) -- BrainsWay, a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, is proud to announce its underwriting of two new Continuing Medical …
Outset Medical Names First Chief Nursing Officer
GlobeNewswire
·
July 30, 2025
SAN JOSE, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced Brittni McGill has been …
Advanced Wound Care Market to Hit $19.32 Billion by 2030 – What’s Fueling the Surge? | MarketsandMarkets™.
GlobeNewswire
·
July 30, 2025
Delray Beach, FL, July 30, 2025 (GLOBE NEWSWIRE) -- The global Advanced Wound Care Market, valued at US$12.48 billion in 2024 stood at US$13.37 billion in 2025 and is projected to advance at a resilient CAGR of 7.6% from 2025 to 2030, culminating in a …
Life Backup Plan by Galacxia, Inc Announces $45K in Funding to Expand Its AI-Powered Health and Safety App
GlobeNewswire
·
July 30, 2025
Aliso Viejo, CA, July 30, 2025 (GLOBE NEWSWIRE) -- Life Backup Plan by Galacxia, Inc, redefining how individuals and care systems manage everything from emergencies to healthcare communication, today announced $45,000 in new funding. The investment will …
Registration Now Open for the 2026 MDA Clinical & Scientific Conference Where Global Leaders in Neuromuscular Disease Research & Care Unite to Drive the Next Breakthroughs March 8-11 in Orlando, FL
GlobeNewswire
·
July 30, 2025
New York, July 30, 2025 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA), leader and innovator of the largest global gathering of the neuromuscular disease community, announced today that registration is open for the 2026 MDA Clinical …
Arbor Biotechnologies Announces First Patient Dosed at Mayo Clinic in the redePHine Phase 1/2 Study of ABO-101, an Investigational Gene Editing Treatment for Primary Hyperoxaluria Type 1
GlobeNewswire
·
July 30, 2025
- ABO-101 was well tolerated with no serious adverse events or dose-limiting toxicities reported in the 28-days following dosing - Phase 1/2 redePHine study (NCT06839235) dose escalation ongoing with enrollment at Mayo Clinic in the US and plans to open …
New York Academy of Medicine Welcomes Three Visionary Leaders to Its Board of Trustees
GlobeNewswire
·
July 30, 2025
New York, NY, July 30, 2025 (GLOBE NEWSWIRE) -- New York Academy of Medicine (NYAM) has appointed three nationally recognized health leaders to its Board of Trustees, reinforcing its commitment to healthier, longer lives for everyone: Debra Albert, DNP, …
Vivos Therapeutics Adds to Management Team to Support Expansion and Growth
GlobeNewswire
·
July 30, 2025
LITTLETON, Colo., July 30, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (NASDAQ: VVOS) (“Vivos” or the “Company”), a pioneering medical technology company revolutionizing the treatment of obstructive sleep apnea (OSA) and snoring, today announced the …
Moleculin Receives Notice of Intent to Grant New European Patent for Annamycin
GlobeNewswire
·
July 30, 2025
– New patent enhances market position in Europe HOUSTON, July 30, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard- …
NeuroStar Announces New Publication in JAACAP Open Highlighting Treatment Efficacy in Depressed Adolescents
GlobeNewswire
·
July 30, 2025
MALVERN, Pa., July 30, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, …
Rein Therapeutics Enters into Agreements for up to $21 Million in Flexible Financing
GlobeNewswire
·
July 30, 2025
AUSTIN, Texas, July 30, 2025 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis …
Tenaya Receives Positive Safety Reviews from Independent DSMBs to Advance Both TN-201 and TN-401 Gene Therapy Clinical Trials as Designed
GlobeNewswire
·
July 30, 2025
Enrollment in Both Dose Cohorts of the MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Hypertrophic Cardiomyopathy (HCM) Complete; Follow-up Data from Cohort 1 and Initial Data from Cohort 2 Expected in Fourth Quarter of 2025 First Patient Dosed in 6E13 …
Ultragenyx to Host Conference Call for Second Quarter 2025 Financial Results and Corporate Update
GlobeNewswire
·
July 30, 2025
NOVATO, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today …
Protagenic Therapeutics Announces Grant of new patent in Japan for its Modified Stilbenoid Program Drug Candidates
GlobeNewswire
·
July 30, 2025
NEW YORK and SANTA BARBARA, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (Nasdaq: PTIX) (the “Company”) today announces that on July 18, 2025, the Japanese Patent Office granted Patent JP 7714571B, a patent which runs until March …
Intelligent Bio Solutions Secures Major Drug Testing Tender with Leading London Transport Operator
GlobeNewswire
·
July 30, 2025
NEW YORK, July 30, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced it has secured a major contract …
NewAmsterdam Pharma Presents Positive Data from BROADWAY Trial Demonstrating Statistically Significant Reductions in Key Alzheimer’s Disease Biomarkers at AAIC 2025
GlobeNewswire
·
July 30, 2025
-- Pre-specified analysis shows obicetrapib significantly reduced absolute levels of plasma p-tau217, a key biomarker of Alzheimer’s disease pathology, in both the full analysis set (p=0.0019) and in ApoE4 carriers (p=0.0215), supporting CETP inhibition as …
Clearmind Medicine Files International Patent Application for Novel Combination Therapy Targeting Weight Loss and Fatty Liver Disease
GlobeNewswire
·
July 30, 2025
Vancouver, Canada, July 30, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to …
SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Combination Therapy Targeting Weight Loss and Fatty Liver Disease
GlobeNewswire
·
July 30, 2025
TEL AVIV, Israel, July 30, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central …